Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: IMMX

Immix Biopharma, Inc.

Healthcare | Biotechnology

No licensed closing price on file for IMMX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Immix Biopharma, Inc. (NASDAQ: IMMX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 01:50 UTC.

What Immix Biopharma, Inc. does

Immix Biopharma is a clinical-stage biopharmaceutical company developing CAR-T cell therapies, with its lead candidate NXC-201 currently being tested in clinical trials for light chain amyloidosis and other serious diseases. NXC-201 has received Regenerative Medicine Advanced Therapy Designation, Orphan Drug Designation from both the FDA and European Commission, and Breakthrough Therapy designation from the FDA for relapsed/refractory AL amyloidosis. The company's N-GENIUS platform generated NXC-201, designed as a next-generation CAR-T therapy. The lead U.S.

Summarized from Immix Biopharma, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Charts

Charts are in the appInteractive charts for IMMX are available in Oxford Ledge.
Open IMMX in Oxford Ledge →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity
Source: SEC EDGAR · Filed 2026-05-29
Most recent filed transactions — May 2026:
  • 2026-05-29DirectorAward6,250—
  • 2026-05-29DirectorAward6,250—
  • 2026-05-29DirectorStock Option (Right to Buy)Award12,500—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →
For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for IMMX and 5,000+ tickers.

Create a free account — keep IMMX
For your agent
GET /api/data?ticker=IMMX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt